Boothbay Fund Management LLC, a prominent investment firm, recently disclosed that it has decreased its ownership in Boston Scientific Co. (NYSE:BSX) by 29.0% during the first quarter of this year. According to the Securities and Exchange Commission, the company sold 80,532 shares of the medical equipment provider’s stock, resulting in a reduction of its stake to 197,512 shares. This move has been followed with great interest and raises significant questions about Boothbay’s strategy and the future prospects of Boston Scientific.
Boston Scientific is a well-known player in the medical equipment industry and has made headlines with its recent quarterly earnings results. On July 27th, the company reported earnings per share (EPS) of $0.53 for the quarter, surpassing analysts’ consensus estimates by $0.04. This strong performance was partly attributed to a net margin of 6.81% and a return on equity of 15.16%. Furthermore, Boston Scientific generated revenue of $3.60 billion during the same period, exceeding market expectations of $3.50 billion.
It is worth noting that Boston Scientific’s revenue demonstrated remarkable growth compared to the previous year, showing a 10.9% increase on a year-over-year basis. These positive results indicate that the company is on track for continued success if it maintains its current trajectory.
Financial analysts have been closely monitoring these developments and experts in this field collectively predict that Boston Scientific Co.’s EPS for this fiscal year will land at approximately 1.99 EPS based on their overall assessment.
The recent actions taken by Boothbay Fund Management LLC have sparked speculation within both financial circles and among industry observers regarding its motivations behind reducing its stake in Boston Scientific Co.. Investors often analyze fund managers’ moves as signals about their assessment of a company’s future profitability and stability.
While it is unclear why Boothbay has chosen to sell off such a substantial portion of its holdings in Boston Scientific, these developments will undoubtedly be scrutinized further to gain insight into the investment firm’s rationale. It is essential to evaluate various factors and consider market conditions that could have influenced this decision.
As always, market participants are encouraged to conduct their own due diligence and analyze comprehensive reports on Boston Scientific Co., such as the latest data provided by renowned industry sources. Keeping up with current market information will further support informed investment decisions and help investors navigate the dynamic financial landscape effectively.
[bs_slider_forecast ticker=”GD”]
Changes in Institutional Shareholder Base Prompt Analysts to Assess Boston Scientific’s Prospects
[stock_market_widget type=”chart” template=”basic” color=”#3946CE” assets=”GD” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” api=”yf”]September 10, 2023 – Boston Scientific (NYSE: BSX), a leading medical equipment provider, has been subject to several changes in its institutional shareholder base. Hedge funds and other institutional investors have made significant adjustments to their positions in the company’s stock.
Liontrust Investment Partners LLP, during the first quarter of this year, acquired a new stake in Boston Scientific valued at $1,002,000. HAP Trading LLC also bought a new stake worth $875,000 within the same period. Intact Investment Management Inc., on the other hand, increased its stake in Boston Scientific by 7.2% during the first quarter. The firm now owns 17,800 shares of the company’s stock valued at $891,000 after purchasing an additional 1,200 shares in the last quarter. Furthermore, Mirova purchased a new stake valued at $435,000 during the first quarter. Finally, Ossiam significantly increased its stake in Boston Scientific by 262.8% during the first quarter and now holds 61,441 shares valued at $3,074,000 after purchasing an additional 44,507 shares.
It is noteworthy that institutional investors currently own approximately 89.11% of Boston Scientific’s stock.
Given these developments with institutional investors’ positions in Boston Scientific’s stock have prompted several analysts to weigh in on its prospects. Royal Bank of Canada reiterated an “outperform” rating and set a target price of $58.00 per share on August 28th. Citigroup restated a “buy” rating with a price target of $63.00 per share on the same day. Analysts from Raymond James upped their price target from $60.00 to $61.00 per share on July 28th following a positive research report.
The consensus among analysts based on Bloomberg data suggests that there is currently a “Moderate Buy” sentiment towards the stock, with an average price target of $58.50.
In other recent news, executives of Boston Scientific have made significant stock transactions. EVP Arthur C. Butcher sold 6,697 shares on June 21st at an average price of $53.80 per share, amounting to a total value of $360,298.60. In a separate transaction, SVP Vance R. Brown sold 15,750 shares on August 25th at an average price of $50.52 per share, resulting in a total value of $795,690.00.
The stock currently trades on the New York Stock Exchange (NYSE) under the symbol BSX and closed at $53.87 on Friday with a trading volume of approximately 4,419,340 shares. Boston Scientific’s stock has had a range between its twelve-month low of $37.74 and its twelve-month high of $54.99.
With a market cap of $78.88 billion and a relatively high PE ratio of 89.78, Boston Scientific continues to be an attractive investment opportunity for many in the medical equipment sector.
Disclaimer: The information provided here should not be considered financial advice or guidance to make investment decisions but is solely for informational purposes.
